These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Le Manach C; Scheurer C; Sax S; Schleiferböck S; Cabrera DG; Younis Y; Paquet T; Street L; Smith P; Ding XC; Waterson D; Witty MJ; Leroy D; Chibale K; Wittlin S Malar J; 2013 Nov; 12():424. PubMed ID: 24237770 [TBL] [Abstract][Full Text] [Related]
5. Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds. Dans MG; Weiss GE; Wilson DW; Sleebs BE; Crabb BS; de Koning-Ward TF; Gilson PR Int J Parasitol; 2020 Mar; 50(3):235-252. PubMed ID: 32135179 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Dual-Stage Malaria Inhibitors with New Targets. Raphemot R; Lafuente-Monasterio MJ; Gamo-Benito FJ; Clardy J; Derbyshire ER Antimicrob Agents Chemother; 2015 Dec; 60(3):1430-7. PubMed ID: 26666931 [TBL] [Abstract][Full Text] [Related]
7. A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets. Dousti M; Manzano-Román R; Rashidi S; Barzegar G; Ahmadpour NB; Mohammadi A; Hatam G Pathog Dis; 2021 Jan; 79(1):. PubMed ID: 33202000 [TBL] [Abstract][Full Text] [Related]
8. Development of a Novel High-Density [3H]Hypoxanthine Scintillation Proximity Assay To Assess Plasmodium falciparum Growth. de Cózar C; Caballero I; Colmenarejo G; Sanz LM; Álvarez-Ruiz E; Gamo FJ; Cid C Antimicrob Agents Chemother; 2016 Oct; 60(10):5949-56. PubMed ID: 27458216 [TBL] [Abstract][Full Text] [Related]
9. Retargeting azithromycin analogues to have dual-modality antimalarial activity. Burns AL; Sleebs BE; Siddiqui G; De Paoli AE; Anderson D; Liffner B; Harvey R; Beeson JG; Creek DJ; Goodman CD; McFadden GI; Wilson DW BMC Biol; 2020 Sep; 18(1):133. PubMed ID: 32993629 [TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867 [TBL] [Abstract][Full Text] [Related]
11. Multi-omic Characterization of the Mode of Action of a Potent New Antimalarial Compound, JPC-3210, Against Birrell GW; Challis MP; De Paoli A; Anderson D; Devine SM; Heffernan GD; Jacobus DP; Edstein MD; Siddiqui G; Creek DJ Mol Cell Proteomics; 2020 Feb; 19(2):308-325. PubMed ID: 31836637 [TBL] [Abstract][Full Text] [Related]
12. Determining the Mode of Action of Antimalarial Drugs Using Time-Resolved LC-MS-Based Metabolite Profiling. Cobbold SA; McConville MJ Methods Mol Biol; 2019; 1859():225-239. PubMed ID: 30421232 [TBL] [Abstract][Full Text] [Related]
13. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. Deniskin R; Frame IJ; Sosa Y; Akabas MH Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473 [TBL] [Abstract][Full Text] [Related]
14. A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery. Almela MJ; Lozano S; Lelièvre J; Colmenarejo G; Coterón JM; Rodrigues J; Gonzalez C; Herreros E PLoS One; 2015; 10(8):e0135139. PubMed ID: 26317851 [TBL] [Abstract][Full Text] [Related]
15. Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy. Watkins WM; Woodrow C; Marsh K Am J Trop Med Hyg; 1993 Jul; 49(1):106-12. PubMed ID: 8352382 [TBL] [Abstract][Full Text] [Related]
16. Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Sosa Y; Deniskin R; Frame IJ; Steiginga MS; Bandyopadhyay D; Graybill TL; Kallal LA; Ouellette MT; Pope AJ; Widdowson KL; Young RJ; Akabas MH ACS Infect Dis; 2019 Oct; 5(10):1738-1753. PubMed ID: 31373203 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of functionalized phthalimides: a new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite. Singh AK; Rajendran V; Pant A; Ghosh PC; Singh N; Latha N; Garg S; Pandey KC; Singh BK; Rathi B Bioorg Med Chem; 2015 Apr; 23(8):1817-27. PubMed ID: 25766631 [TBL] [Abstract][Full Text] [Related]
18. A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. Bahamontes-Rosa N; Rodríguez-Alejandre A; González-del-Rio R; García-Bustos JF; Mendoza-Losana A Mol Biochem Parasitol; 2012 Feb; 181(2):171-7. PubMed ID: 22108433 [TBL] [Abstract][Full Text] [Related]
19. Protective activity of biflavanones from Garcinia kola against Plasmodium infection. Konziase B J Ethnopharmacol; 2015 Aug; 172():214-8. PubMed ID: 26129936 [TBL] [Abstract][Full Text] [Related]
20. Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates. Chirawurah JD; Ansah F; Nyarko PB; Duodu S; Aniweh Y; Awandare GA Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):399-406. PubMed ID: 29128848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]